<DOC>
<DOCNO>
EP-0015658
</DOCNO>
<TEXT>
<DATE>
19800917
</DATE>
<IPC-CLASSIFICATIONS>
A61K-31/19 C07C-405/00 A61P-9/08 A61K-31/215 A61K-31/185 A61P-9/00 A61P-9/10 A61K-31/21 A61K-31/557 <main>A61K-9/06</main> 
</IPC-CLASSIFICATIONS>
<TITLE>
topical compositions containing prostaglandine derivatives.
</TITLE>
<APPLICANT>
american cyanamid cous<sep>american cyanamid company<sep>american cyanamid companyberdan avenuewayne new jersey 06904us<sep>american cyanamid company<sep>
</APPLICANT>
<INVENTOR>
birnbaum jay edward<sep>dessy franz<sep>van humbeeck luc<sep>birnbaum, jay edward<sep>dessy, franz<sep>van humbeeck, luc<sep>birnbaum, jay edward46 tamarack lanepomona new yorkus<sep>dessy, franz66 rue notre-dame-auboixb-1140 braine le chateaube<sep>van humbeeck, luc15 rue aderchampb-1430 wauthier-brainebe<sep>birnbaum, jay edward  <sep>dessy, franz<sep>van humbeeck, luc<sep>birnbaum, jay edward46 tamarack lanepomona new yorkus<sep>dessy, franz66 rue notre-dame-auboixb-1140 braine le chateaube<sep>van humbeeck, luc15 rue aderchampb-1430 wauthier-brainebe<sep>
</INVENTOR>
<ABSTRACT>
there are provided topical pharmaceutical composi­ tions for producing cutaneous vasodilation in the treatment  of vasospastic or ischemic conditions containing a natural  or synthetic prostaglandin analog of the pge, pga or  pgfβ types.  the carrier for the active component of these  compositions is either one which is adapted to accomplish  direct contact between the prostaglandin and the surface  of the skin of the patient to be treated, or is a sterile in­ jectable fluid.  
</ABSTRACT>
</TEXT>
</DOC>
